HC Wainwright Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $49.00
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
BioSpace1d
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
FiercePharma3d
Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
44,623 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Purchased by Intech Investment Management LLC
Intech Investment Management LLC acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd ...
BridgeBio: Next Chapter Begins After Attruby Approval
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
BridgeBio Pharma: FDA Endorsement and Stable Price Target Bolster Buy Rating
Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...
BridgeBio Selects PANTHERx® Rare Specialty Pharmacy for Distribution of Attruby™ (acoramidis)
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...